Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.

PloS one - 1 Jan 2015

Liu Lin L, Li Fei, Pao William, Michor Franziska

Abstract excerpt

BACKGROUND: The advent of targeted therapy for cancer treatment has brought about a paradigm shift in the clinical management of human malignancies. Agents such as erlotinib used for EGFR-mutant non-small cell lung cancer or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor responses. Unfortunately, however, resistance often emerges and renders these agents ineffective after a variable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Models, Theoretical

Share to Mutation Rate

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 26536620
DOI: 10.1371/journal.pone.0141665
PMCID: PMC4633116

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.PMID 26536620Read ↗

Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.Semantic proximity Read ↗

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.Semantic proximity Read ↗

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration StrategiesSemantic proximity Read ↗

Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.Semantic proximity Read ↗

Drug-induced resistance evolution necessitates less aggressive treatmentSemantic proximity Read ↗

Drug-induced resistance evolution necessitates less aggressive treatment.Semantic proximity Read ↗

Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.Semantic proximity Read ↗

Drug resistance in cancer: Principles of emergence and preventionSemantic proximity Read ↗

Dosage strategies for delaying resistance emergence in heterogeneous tumors.Semantic proximity Read ↗

Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.Semantic proximity Read ↗

Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer TreatmentSemantic proximity Read ↗

Frequency-dependent ecological interactions increase the prevalence, and shape the distribution, of pre-existing drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.